Ogushi K, Chuma M, Uojima H, et al. - This inquiry was performed in Child-Pugh class A (CP-A) and class B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC), to determine the safety, efficacy as well as the prognostic effect of clinical factors associated with lenvatinib treatment in this sample of patients. Researchers retrospectively examined patients with u-HCC who underwent lenvatinib treatment at multiple centers in Japan. Radiological objective response (OR) was evaluated. CP-B vs CP-A patients had higher frequency of lenvatinib-related adverse events. A markedly higher OR rate (44.0%) was noted in CP-A5 patients vs CP-A6 (25.5%), CP-B7 (22.2%), and CP-B8 patients (5.3%), respectively. Findings showed that patients with good liver function experienced significant benefits of lenvatinib treatment in real-world practice. This work affords several characteristics that might aid as clinical predictors of response to lenvatinib and survival in clinical practice.